French drugmaker Sanofi showcased its vaccine franchise, part of a promise made two years ago to overhaul what the company at the time acknowledged was a lagging part of its business.
Ahead of an event in London on Thursday, the company previewed new data from a dozen vaccine products in development, including two mRNA-based flu shots, RSV products, a pneumococcal vaccine, vaccines for meningitis B and chlamydia, and a therapeutic acne vaccine. Two of those — an RSV vaccine and a pneumococcal vaccine — are slated to enter Phase III in the first half of 2024.
Preview
Source: EndPoints
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.